Chinese investors lead another monster round for Menlo Park early cancer detection unicorn
Looking to detect cancer early through a simple blood test, Grail Inc. scored $300 million in new funding from several Chinese investors on top of the $1.2 billion it raised over the past two years.
The Menlo Park company, which was rumored to be planning a $500 million initial public offering in Hong Kong later this year, said the oversubscribed Series C round will help it develop and validate experimental products for early cancer detection.
PitchBook Data  estimated that Grail was valued at…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | China Health | Funding | Health Management | Hong Kong Health | Men